Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Am J Nephrol
    March 2021
  1. CHEMOUNY JM, Bobot M, Sannier A, Maisons V, et al
    Kidney Biopsy in Type 2 Diabetes: A Multicenter Cross-Sectional Study.
    Am J Nephrol. 2021 Mar 29:1-10. doi: 10.1159/000514259.
    >> Share

  2. LAZARO-GUEVARA J, Fierro-Morales J, Wright AH, Gunville R, et al
    Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Diabetic Kidney Disease.
    Am J Nephrol. 2021 Mar 26:1-11. doi: 10.1159/000514578.
    >> Share

    October 2020
  3. LIMONTE CP, Valo E, Montemayor D, Afshinnia F, et al
    A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes.
    Am J Nephrol. 2020 Oct 14:1-10. doi: 10.1159/000510830.
    >> Share

    September 2020
  4. WANG X, Zhang H, Zhang Q, Guan M, et al
    Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Am J Nephrol. 2020 Sep 23:1-9. doi: 10.1159/000510255.
    >> Share

    April 2020
  5. SCHOINA M, Loutradis C, Minopoulou I, Theodorakopoulou M, et al
    Ambulatory Blood Pressure Trajectories and Blood Pressure Variability in Diabetic and Non-Diabetic Chronic Kidney Disease.
    Am J Nephrol. 2020 Apr 7:1-10. doi: 10.1159/000507416.
    >> Share

  6. MARATHIAS KP, Lambadiari VA, Markakis KP, Vlahakos VD, et al
    Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Am J Nephrol. 2020 Apr 2:1-8. doi: 10.1159/000507272.
    >> Share

    March 2020
  7. WEIR MR, McCullough PA, Buse JB, Anderson J, et al
    Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation
    Am J Nephrol. 2020 Mar 13:1-13. doi: 10.1159/000506533.
    >> Share

    December 2019
  8. JIANG S, Fang J, Yu T, Liu L, et al
    Novel Model Predicts Diabetic Nephropathy in Type 2 Diabetes.
    Am J Nephrol. 2019 Dec 19:1-9. doi: 10.1159/000505145.
    >> Share

  9. CHERNEY DZI, Repetto E, Wheeler DC, Arnold SV, et al
    Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
    Am J Nephrol. 2019 Dec 6:1-9. doi: 10.1159/000504558.
    >> Share

    October 2019
  10. RUILOPE LM, Agarwal R, Anker SD, Bakris GL, et al
    Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Am J Nephrol. 2019 Oct 30:1-12. doi: 10.1159/000503712.
    >> Share

  11. BAKRIS GL, Agarwal R, Anker SD, Pitt B, et al
    Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Am J Nephrol. 2019 Oct 25:1-12. doi: 10.1159/000503713.
    >> Share

    June 2019
  12. COMAI G, Malvi D, Angeletti A, Vasuri F, et al
    Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis.
    Am J Nephrol. 2019 Jun 5:1-8. doi: 10.1159/000500353.
    >> Share

  13. LEE J, Chu C, Guzman D, Fontil V, et al
    Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.
    Am J Nephrol. 2019 Jun 5:1-7. doi: 10.1159/000500706.
    >> Share

    March 2019
  14. WOODS TC, Satou R, Miyata K, Katsurada A, et al
    Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Am J Nephrol. 2019;49:331-342.
    >> Share

  15. BURNS KD, Cherney D
    Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease.
    Am J Nephrol. 2019;49:328-330.
    >> Share

    January 2019
  16. RUGGENENTI P, Remuzzi G
    Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.
    Am J Nephrol. 2019;49:143-145.
    >> Share

  17. ANYANWAGU U, Donnelly R, Idris I
    Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort.
    Am J Nephrol. 2019;49:146-155.
    >> Share

    May 2018
  18. YAMAMOTO CM, Murakami T, Oakes ML, Mitsuhashi M, et al
    Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus.
    Am J Nephrol. 2018;47:283-291.
    >> Share

    January 2018
  19. CHIN MP, Bakris GL, Block GA, Chertow GM, et al
    Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
    Am J Nephrol. 2018;47:40-47.
    >> Share

  20. TRIEBSWETTER S, Gutjahr-Lengsfeld LJ, Schmidt KR, Drechsler C, et al
    Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 Diabetes.
    Am J Nephrol. 2018;47:30-39.
    >> Share

    December 2017
  21. JARDINE MJ, Mahaffey KW, Neal B, Agarwal R, et al
    The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Am J Nephrol. 2017;46:462-472.
    >> Share

  22. NEUMILLER JJ, Rhee CM, Kalantar-Zadeh K
    Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy.
    Am J Nephrol. 2017;46:459-461.
    >> Share

    September 2017
  23. SAULNIER PJ, Dieter BP, Tanamas SK, McPherson SM, et al
    Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
    Am J Nephrol. 2017;46:276-284.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016